The Effects of Prior Lines of Therapy on Clinical Outcomes for Patients with Chronic Graft-Versus-Host Disease Receiving Axatilimab: A Post Hoc Analysis of Agave-201

Dr. Catherine Lee presents a post-hoc analysis of the AGAVE-201 trial, demonstrating that axatilimab achieves consistent overall response rates in patients with chronic graft-versus-host disease regardless of prior lines of therapy, with rapid and durable responses, particularly following ruxolitinib, and a favorable safety profile.